Literature DB >> 27346190

Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.A11.

Susanne K Hansen1, Helena Borland2, Lis F Hasholt3, Zeynep Tümer4, Jørgen E Nielsen5, Mikkel A Rasmussen6, Troels T Nielsen7, Tina C Stummann2, Karina Fog2, Poul Hyttel8.   

Abstract

Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited neurodegenerative disease caused by a CAG-repeat expanding mutation in ATXN3. We generated induced pluripotent stem cells (iPSCs) from a SCA3 patient by electroporation of dermal fibroblasts with episomal plasmids encoding L-MYC, LIN28, SOX2, KLF4, OCT4 and short hairpin RNA targeting P53. The resulting iPSCs had normal karyotype, were free of genomically integrated episomal plasmids, expressed pluripotency markers, could differentiate into the three germ layers in vitro and retained the disease-causing ATXN3 mutation. This iPSC line could be useful for the investigation of SCA3 disease mechanisms.
Copyright © 2016 Roslin Cells Ltd. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27346190     DOI: 10.1016/j.scr.2016.02.040

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  3 in total

1.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

2.  Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications.

Authors:  Aline Yen Ling Wang; Charles Yuen Yung Loh
Journal:  Cell Transplant       Date:  2019-11-14       Impact factor: 4.064

Review 3.  Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias.

Authors:  Bart P C van de Warrenburg; Hans van Bokhoven; Marina P Hommersom; Ronald A M Buijsen; Willeke M C van Roon-Mom
Journal:  Stem Cell Rev Rep       Date:  2021-05-25       Impact factor: 5.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.